CMS makes it official: Coverage for new Alzheimer's drugs once full approvals arrive
As Congressional and advocacy group pressure has been heated, the Centers for Medicare and Medicaid Services reaffirmed today that if amyloid-targeted drugs to slow the progression of Alzheimer’s disease win full approval — not just accelerated approval — then Medicare will cover treatment where real-world data can be collected.
The official coverage-is-coming announcement, which had been previously mentioned by Eisai, Biogen and CMS officials separately, arrives as Eisai and Biogen’s Leqembi (lecanemab) faces an advisory committee meeting of outside FDA experts next Friday.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
